Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 337

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 337
---
 risk related to the Company’s cash equivalents, short-term investments and non-current financial assets is not significant in light of the quality of the issuers. The Company deemed that none of the instruments in its portfolio are exposed to credit risk.

Fair value

The fair value of financial instruments traded on an active market is based on the market rate as of December 31, 2024. The market prices used for the financial assets owned by the Company are the bid prices in effect on the market as of the valuation date.

4)Cash, cash equivalents and financial assets

                                                            December 31                                        
  (in thousands of euro)                                           2022                                        
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Cash and cash equivalents                                                   84,225       70,605      66,396  
  Short-term investments                                                      17,260       21,851      14,374  
  Cash and cash equivalents and short-term investments                       101,485       92,456      80,770  
  Non-current financial assets                                                35,119        9,796      10,281  
  Total cash, cash equivalents and financial assets                          136,604      102,252      91,051  

Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts, fixed-term accounts and mutual funds units (with short-term maturities) held with various banking institutions.

Other non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity.

As of December 31, 2022, 2023 and 2024 the amount of cash, cash equivalents and financials assets denominated in U. S. dollars amounted respectively to € 34,735 20,798 16,529

F-35

The variation of short-term investments and non-current financial assets for the periods presented, are the following:

  (in thousands of euro)            December 31, 2021                  Deductions (2)      Variance of fair value through the consolidated statement of income (loss)      Variance of accrued interests      Foreign currency effect              
  Short-term investments                                   16,080      —                                                                                          268      —                                  912                          17,260  
  Non-current financial assets                             39,878      (